Kutsogiannis Demetrios J, Alharthy Abdulrahman, Balhamar Abdullah, Faqihi Fahad, Papanikolaou John, Alqahtani Saleh A, Memish Ziad A, Brindley Peter G, Brochard Laurent, Karakitsos Dimitrios
Department of Critical Care Medicine, Faculty of Medicine and Dentistry, The University of Alberta, Edmonton, AB, Canada.
Critical Care Department, King Saud Medical City, Riyadh, Saudi Arabia.
Front Med (Lausanne). 2022 Mar 4;9:800241. doi: 10.3389/fmed.2022.800241. eCollection 2022.
There may be a difference in respiratory mechanics, inflammatory markers, and pulmonary emboli in COVID-19 associated ARDS vs. ARDS from other etiologies. Our purpose was to determine differences in respiratory mechanics, inflammatory markers, and incidence of pulmonary embolism in patients with and without COVID-19 associated ARDS admitted in the same period and treated with a similar ventilation strategy.
A cohort study of COVID-19 associated ARDS and non COVID-19 patients in a Saudi Arabian center between June 1 and 15, 2020. We measured respiratory mechanics (ventilatory ratio (VR), recruitability index (RI), markers of inflammation, and computed tomography pulmonary angiograms.
Forty-two patients with COVID-19 and 43 non-COVID patients with ARDS comprised the cohort. The incidence of "recruitable" patients using the recruitment/inflation ratio was slightly lower in COVID-19 patients (62 vs. 86%; = 0.01). Fifteen COVID-19 ARDS patients (35.7%) developed a pulmonary embolism as compared to 4 (9.3%) in other ARDS patients ( = 0.003). In COVID-19 patients, a D-Dimer ≥ 5.0 mcg/ml had a 73% (95% CI 45-92%) sensitivity and 89% (95% CI 71-98%) specificity for predicting pulmonary embolism. Crude 60-day mortality was higher in COVID-19 patients (35 vs. 15%; = 0.039) but three multivariate analysis showed that independent predictors of 60-day mortality included the ventilatory ratio (OR 3.67, 95% CI 1.61-8.35), PaO2/FIO2 ratio (OR 0.93; 95% CI 0.87-0.99), IL-6 (OR 1.02, 95% CI 1.00-1.03), and D-dimer (OR 7.26, 95% CI 1.11-47.30) but not COVID-19 infection.
COVID-19 patients were slightly less recruitable and had a higher incidence of pulmonary embolism than those with ARDS from other etiologies. A high D-dimer was predictive of pulmonary embolism in COVID-19 patients. COVID-19 infection was not an independent predictor of 60-day mortality in the presence of ARDS.
新型冠状病毒肺炎(COVID-19)相关急性呼吸窘迫综合征(ARDS)与其他病因所致ARDS在呼吸力学、炎症标志物及肺栓塞方面可能存在差异。我们的目的是确定同期收治且采用相似通气策略治疗的COVID-19相关ARDS患者与非COVID-19相关ARDS患者在呼吸力学、炎症标志物及肺栓塞发生率方面的差异。
对沙特阿拉伯某中心2020年6月1日至15日期间的COVID-19相关ARDS患者和非COVID-19患者进行队列研究。我们测量了呼吸力学(通气比(VR)、可复张性指数(RI))、炎症标志物,并进行了计算机断层扫描肺动脉造影。
该队列包括42例COVID-19患者和43例非COVID-19的ARDS患者。采用复张/充气比时,COVID-19患者中“可复张”患者的发生率略低(62%对86%;P = 0.01)。15例COVID-19相关ARDS患者(35.7%)发生了肺栓塞,而其他ARDS患者中有4例(9.3%)发生肺栓塞(P = 0.003)。在COVID-19患者中,D-二聚体≥5.0 mcg/ml对预测肺栓塞的敏感性为73%(95%可信区间45 - 9二%),特异性为89%(95%可信区间71 - 98%)。COVID-19患者的粗60天死亡率更高(35%对15%;P = 0.039),但多因素分析显示,60天死亡率的独立预测因素包括通气比(比值比3.67,95%可信区间1.61 - 8.35)、动脉血氧分压/吸入氧分数值(比值比0.93;95%可信区间0.87 - 0.99)、白细胞介素-6(比值比1.02,95%可信区间1.00 - 1.03)和D-二聚体(比值比7.26,95%可信区间1.11 - 47.30),但不包括COVID-19感染。
与其他病因所致ARDS患者相比,COVID-19患者的可复张性略低,肺栓塞发生率更高。高D-二聚体可预测COVID-19患者发生肺栓塞。在存在ARDS的情况下,COVID-19感染不是60天死亡率的独立预测因素。